Skip to main navigation
Avadel Pharmaceuticals
  • Recent News
  • Investors
  • About
    • Overview
    • Leadership
    • Board of Directors
    • Business Development
    • Corporate Responsibility
  • Products
    • Hospital
      • Bloxiverz ®
      • Vazculep ®
      • Akovaz ®
  • Research
    • Clinical Trials
  • Contact Us
  • Call Today
  • Email Us
  • Our Map
    • Avadel Pharmaceuticals
    • 636.449.1830
    • Home
    • About
      • Overview
      • Leadership
      • Board of Directors
      • Business Development
      • Corporate Responsibility
    • Products
      • Hospital
        • Bloxiverz ®
        • Vazculep ®
        • Akovaz ®
    • Research Pipeline
      • Clinical Trials
    • Investor Relations

      • Investors
      • News & Events
        • Press Releases
        • Investor Calendar
        • Presentations
      • Stock Information
        • Stock Quote & Chart
        • Historical Price Lookup
        • Investment Calculator
      • Financial Information
        • SEC Filings
        • Financial Reports
        • Quarterly Results
      • Corporate Governance
        • Governance Highlights
        • Management Team
        • Board of Directors
        • Committee Composition
        • Annual General Meeting
      • Shareholder Services
        • Investor FAQs
        • Information Request
        • E-mail Alerts
        • IR Contacts
    • Contact Us
646.449.1830

Breadcrumb

  1. Home
  2. Investors
  3. Press Releases

Press Releases

Keyword Search

12/02/19

Avadel Pharmaceuticals Announces Key Appointments to Leadership Team To Support Continued Transformation and the Advancement of FT218
- - - Thomas S. McHugh appointed as Chief Financial Officer - - - Dr. Jason Vaughn appointed Senior ...
Printer Friendly Version
11/25/19

Avadel Pharmaceuticals Achieves Enrollment Target in REST-ON Phase 3 Pivotal Trial of FT218 for Excessive Daytime Sleepiness and Cataplexy in Patients with Narcolepsy
205 patients enrolled; additional patients currently in screening will be allowed to enroll if eligi...
Printer Friendly Version
11/21/19

Avadel Pharmaceuticals to Present at Two Upcoming Investor Conferences
DUBLIN, Ireland , Nov. 21, 2019 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a com...
Printer Friendly Version
11/12/19

Avadel Pharmaceuticals Reports Third Quarter 2019 Financial Results and Raises Revenue Guidance for FY2019
Enrollment currently at 200 patients for the pivotal REST-ON Phase 3 study (97.5% complete); the Com...
Printer Friendly Version
10/29/19

Avadel Pharmaceuticals to Report Third Quarter 2019 Financial Results on November 12th
DUBLIN, Ireland , Oct. 29, 2019 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a com...
Printer Friendly Version
10/04/19

Avadel Announces Resignation of Kevin Kotler from Board of Directors
DUBLIN, Ireland , Oct. 04, 2019 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a com...
Printer Friendly Version
09/24/19

Avadel Pharmaceuticals Announces Pharmacokinetic (PK) Data for Once-Nightly FT218 that will be Included in an Oral Presentation at the World Sleep 2019 Congress on September 25th
DUBLIN, Ireland , Sept. 24, 2019 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a co...
Printer Friendly Version
09/23/19

Avadel Pharmaceuticals Announces FDA Agreement to Reduce the Sample Size for the Ongoing Pivotal Phase 3 Study for Once-Nightly FT218; Full Enrollment Now Expected by End of 2019
  FDA agrees with Company’s proposed changes to the statistical analysis plan for the REST-ON Phase ...
Printer Friendly Version
09/18/19

Avadel Pharmaceuticals Announces an Oral Presentation on Investigational Once-Nightly Sodium Oxybate (FT218) at the World Sleep 2019 Congress on September 25th
DUBLIN, Ireland , Sept. 18, 2019 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a co...
Printer Friendly Version
09/17/19

Avadel Pharmaceuticals to Present at the Ladenburg Thalmann 2019 Healthcare Conference on September 24th
DUBLIN, Ireland , Sept. 17, 2019 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a co...
Printer Friendly Version
08/09/19

Avadel Pharmaceuticals Reports Second Quarter 2019 Financial Results and Provides Company Update
Better-than-expected Hospital Product revenue improves liquidity position Restructuring and other co...
Printer Friendly Version
08/08/19

Avadel Pharmaceuticals Receives New PDUFA Date for AV001 of December 15, 2019
PDUFA Action Extended 3 Months; Launch Remains on Track for 1Q 2020 DUBLIN, Ireland , Aug. 08, 2019 ...
Printer Friendly Version
08/01/19

Avadel Pharmaceuticals Further Strengthens Clinical and Medical Team
Appoints Courtney Wells as Vice President, Clinical Operations; and David Seiden, M.D., as Senior Me...
Printer Friendly Version
07/29/19

Avadel Pharmaceuticals to Report Second Quarter 2019 Financial Results
DUBLIN, Ireland , July 29, 2019 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a com...
Printer Friendly Version
06/04/19

Avadel to Present New Data on Once-Nightly Sodium Oxybate at SLEEP 2019 Conference
DUBLIN, Ireland , June 04, 2019 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a com...
Printer Friendly Version
06/03/19

Avadel Pharmaceuticals Appoints Gregory J. Divis Chief Executive Officer
DUBLIN, Ireland , June 03, 2019 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a com...
Printer Friendly Version
05/22/19

Avadel Pharmaceuticals Announces FDA Acceptance of New Drug Application for AV001
AV001 granted Priority Review PDUFA action date is September 15, 2019 DUBLIN, Ireland , May 22, 2019...
Printer Friendly Version
05/08/19

Avadel Pharmaceuticals Reports First Quarter 2019 Financial Results
REST-ON 63% enrolled; 98 patients remain to be enrolled   Jordon Dubow , M.D., appointed as Chief Me...
Printer Friendly Version
04/29/19

Avadel Pharmaceuticals Announces Appointment of Jordan Dubow, M.D., as Chief Medical Officer
DUBLIN, Ireland , April 29, 2019 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a co...
Printer Friendly Version
04/29/19

Avadel Pharmaceuticals to Report First Quarter 2019 Financial Results
DUBLIN, Ireland , April 29, 2019 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a co...
Printer Friendly Version
03/15/19

Avadel Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results
DUBLIN, Ireland , March 15, 2019 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a co...
Printer Friendly Version
03/07/19

Avadel Pharmaceuticals to Report Fourth Quarter and Full Year 2018 Financial Results
DUBLIN, Ireland , March 07, 2019 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a co...
Printer Friendly Version
02/07/19

Avadel Pharmaceuticals Clarifies Announcement of Corporate Restructuring
DUBLIN, Ireland , Feb. 07, 2019 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL) provid...
Printer Friendly Version
02/07/19

Avadel Pharmaceuticals Announces Restructuring to Focus on FT218 Clinical Development Program
- Company cost structure expected to be reduced by $70 to $75 million in 2019 – - Approximately $100...
Printer Friendly Version
01/23/19

‘Sleep Normal’ campaign urges Americans to end frequent nighttime urination and stop settling for nights of bad sleep
Nearly 50 million Americans wake up to urinate more than once per night due to a treatable medical c...
Printer Friendly Version
01/03/19

Avadel Pharmaceuticals Announces Changes to Management Team and Board of Directors
- Michael S. Anderson resigns as Chief Executive Officer and member of Avadel’s Board of Directors –...
Printer Friendly Version

Tools

  • Print Page
  • RSS
  • E-mail Alerts

Investor Relations

  • Investors
  • News & Events
    • Press Releases
    • Investor Calendar
    • Presentations
  • Stock Information
    • Stock Quote & Chart
    • Historical Price Lookup
    • Investment Calculator
  • Financial Information
    • SEC Filings
    • Financial Reports
    • Quarterly Results
  • Corporate Governance
    • Governance Highlights
    • Management Team
    • Board of Directors
    • Committee Composition
    • Annual General Meeting
  • Shareholder Services
    • Investor FAQs
    • Information Request
    • E-mail Alerts
    • IR Contacts

Contact Avadel Pharmaceuticals Today

Avadel Pharmaceuticals

Helpful Links Site Map | Privacy Policy | Terms and Conditions

  • Overview
  • News & Events
  • Careers
  • Investors
  • Contact Us
16640 Chesterfield Grove Road,
Suite 200,
Saint Louis, MO 63005 |  View Map [+]
http://www.avadel.com/
Site Map | Privacy Policy
http://www.avadel.com/

© COPYRIGHT AVADEL PHARMACEUTICALS, PLC. ALL RIGHTS RESERVED

0117 AVL WBST MAIN_KP2